Targeting DNA Repair in Metastatic Pancreatic and Prostate Cancers
PARP inhibitors benefit observed beyond treatment for breast and ovarian cancers
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML With a FLT3 Mutation
Approval is based on evidence from the ADMIRAL trial
GITR Is an Attractive Target for Immunotherapy
Targeting alternative immune pathways
EMA Grants a Positive Opinion for LysaKare (Arginine/lysine)
It is intended for protecting the kidneys against radiation during PRRT with lutetium (177Lu) oxodotreotide.
FDA Approves Alpelisib for Metastatic Breast Cancer
It also approved the companion diagnostic test to select patients who have PIK3CA mutations in tumour tissue specimens and/or in ctDNA
Combination Immunotherapies for Immune Hot, Altered and Cold Tumours
Understanding underlining mechanisms is crucial to boost a weak antitumour immunity
FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease
It is approved for steroid-refractory GVHD in adult and paediatric patients 12 years and older
IMMUNOTARGET Registry in Advanced NSCLC With Oncogenic Driver Alterations
Patients with actionable tumour alterations should receive targeted therapies and chemotherapy before considering immunotherapy
Measuring Financial Toxicity After Cancer Diagnosis and Treatment
Available instruments may not be capable of ascertaining all relevant domains
FDA Approves Dalteparin Sodium for Venous Thromboembolism in Paediatric Patients
Approval is based on evidence from two clinical trials in paediatric patients with or without cancer
Deep Learning Model’s Potential to Increase the Accuracy of Lung Cancer Screening
Automated prediction of malignancy risk of pulmonary nodules in chest CT scan
Rendering the Tumour Microenvironment More Sensitive to PD-1 Blockade
Results of the TONIC trial